{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:14:34Z","timestamp":1773278074188,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,1,5]],"date-time":"2011-01-05T00:00:00Z","timestamp":1294185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s00280-010-1509-4","type":"journal-article","created":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T06:14:52Z","timestamp":1294121692000},"page":"827-833","source":"Crossref","is-referenced-by-count":20,"title":["Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi\u2019s sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial"],"prefix":"10.1007","volume":"68","author":[{"given":"Mary","family":"Cianfrocca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Von Roenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce J.","family":"Dezube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Krown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,5]]},"reference":[{"key":"1509_CR1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/(SICI)1097-0215(19961211)68:6<754::AID-IJC11>3.0.CO;2-0","volume":"68","author":"RJ Biggar","year":"1996","unstructured":"Biggar RJ, Rosenberg PS, Cote T (1996) Kaposi\u2019s sarcoma, non-Hodgkin\u2019s lymphoma following the diagnosis of AIDS. Multistate AIDS\/cancer match study group. Int J Cancer 68:754\u2013758","journal-title":"Int J Cancer"},{"key":"1509_CR2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJM199505043321801","volume":"332","author":"PS Moore","year":"1995","unstructured":"Moore PS, Chang Y (1995) Detection of herpesvirus-like DNA sequences in Kaposi\u2019s sarcoma in patients with and without HIV infection. N Engl J Med 332:1181\u20131185","journal-title":"N Engl J Med"},{"key":"1509_CR3","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","volume":"266","author":"Y Chang","year":"1994","unstructured":"Chang Y, Cesarman E, Pessin MS et al (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma. Science 266:1865\u20131869","journal-title":"Science"},{"key":"1509_CR4","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1073\/pnas.94.3.979","volume":"94","author":"R Masood","year":"1997","unstructured":"Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS (1997) Vascular endothelial growth factor\/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA 94:979\u2013984","journal-title":"Proc Natl Acad Sci USA"},{"key":"1509_CR5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4161\/cc.6.4.3843","volume":"6","author":"S Montaner","year":"2007","unstructured":"Montaner S (2007) Akt\/TSC\/mTOR activation by the KSHV G protein-coupled receptor: emerging insights into the molecular oncogenesis and treatment of Kaposi\u2019s sarcoma. Cell Cycle 6:438\u2013443","journal-title":"Cell Cycle"},{"key":"1509_CR6","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1128\/JVI.02024-06","volume":"81","author":"Y Zeng","year":"2007","unstructured":"Zeng Y, Zhang X, Huang Z et al (2007) Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi\u2019s sarcoma-associated herpesvirus: role of JAK\/STAT signaling. J Virol 81:2401\u20132417","journal-title":"J Virol"},{"key":"1509_CR7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood-2003-07-2533","volume":"104","author":"Y Aoki","year":"2004","unstructured":"Aoki Y, Tosato G (2004) HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood 104:810\u2013814","journal-title":"Blood"},{"key":"1509_CR8","doi-asserted-by":"crossref","first-page":"25195","DOI":"10.1074\/jbc.M200921200","volume":"277","author":"MC Deregibus","year":"2002","unstructured":"Deregibus MC, Cantaluppi V, Doublier S et al (2002) HIV-1-Tat protein activates phosphatidylinositol 3-kinase\/AKT-dependent survival pathways in Kaposi\u2019s sarcoma cells. J Biol Chem 277:25195\u201325202","journal-title":"J Biol Chem"},{"key":"1509_CR9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJM199508173330710","volume":"333","author":"DD Ho","year":"1995","unstructured":"Ho DD (1995) Time to hit HIV, early and hard. N Engl J Med 333:450\u2013451","journal-title":"N Engl J Med"},{"key":"1509_CR10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJ Palella Jr","year":"1998","unstructured":"Palella FJ Jr, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 338:853\u2013860","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1509_CR11","first-page":"S34","volume":"21","author":"LP Jacobson","year":"1999","unstructured":"Jacobson LP, Yamashita TE, Detels R et al (1999) Impact of potent antiretroviral therapy on the incidence of Kaposi\u2019s sarcoma and non-Hodgkin\u2019s lymphomas among HIV-1-infected individuals. Multicenter AIDS cohort study. J Acquir Immune Defic Syndr 21(Suppl 1):S34\u2013S41","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1509_CR12","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","volume":"338","author":"C Flexner","year":"1998","unstructured":"Flexner C (1998) HIV-protease inhibitors. N Engl J Med 338:1281\u20131292","journal-title":"N Engl J Med"},{"key":"1509_CR13","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.2174\/092986707782360141","volume":"14","author":"A Mastrolorenzo","year":"2007","unstructured":"Mastrolorenzo A, Rusconi S, Scozzafava A, Barbaro G, Supuran CT (2007) Inhibitors of HIV-1 protease: current state of the art 10\u00a0years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr Med Chem 14:2734\u20132748","journal-title":"Curr Med Chem"},{"key":"1509_CR14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1124\/dmd.107.016089","volume":"35","author":"V Dixit","year":"2007","unstructured":"Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD (2007) Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 35:1853\u20131859","journal-title":"Drug Metab Dispos"},{"key":"1509_CR15","first-page":"208","volume":"6","author":"A Jackson","year":"2004","unstructured":"Jackson A, Taylor S, Boffito M (2004) Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors. AIDS Rev 6:208\u2013217","journal-title":"AIDS Rev"},{"key":"1509_CR16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00002018-199920020-00005","volume":"20","author":"LI Malaty","year":"1999","unstructured":"Malaty LI, Kuper JJ (1999) Drug interactions of HIV protease inhibitors. Drug Saf 20:147\u2013169","journal-title":"Drug Saf"},{"key":"1509_CR17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cncr.10634","volume":"95","author":"A Tulpule","year":"2002","unstructured":"Tulpule A, Groopman J, Saville MW et al (2002) Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 95:147\u2013154","journal-title":"Cancer"},{"key":"1509_CR18","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.1999.17.6.1876","volume":"17","author":"PS Gill","year":"1999","unstructured":"Gill PS, Tulpule A, Espina BM et al (1999) Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi\u2019s sarcoma. J Clin Oncol 17:1876\u20131883","journal-title":"J Clin Oncol"},{"key":"1509_CR19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.1998.16.3.1112","volume":"16","author":"L Welles","year":"1998","unstructured":"Welles L, Saville MW, Lietzau J et al (1998) Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi\u2019s sarcoma. J Clin Oncol 16:1112\u20131121","journal-title":"J Clin Oncol"},{"key":"1509_CR20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0140-6736(95)92654-2","volume":"346","author":"MW Saville","year":"1995","unstructured":"Saville MW, Lietzau J, Pluda JM et al (1995) Treatment of HIV-associated Kaposi\u2019s sarcoma with paclitaxel. Lancet 346:26\u201328","journal-title":"Lancet"},{"key":"1509_CR21","first-page":"4026","volume":"54","author":"JW Harris","year":"1994","unstructured":"Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026\u20134035","journal-title":"Cancer Res"},{"key":"1509_CR22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","volume":"94","author":"A Sparreboom","year":"1997","unstructured":"Sparreboom A, van Asperen J, Mayer U et al (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031\u20132035","journal-title":"Proc Natl Acad Sci USA"},{"key":"1509_CR23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2165\/00003088-199427040-00002","volume":"27","author":"DS Sonnichsen","year":"1994","unstructured":"Sonnichsen DS, Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27:256\u2013269","journal-title":"Clin Pharmacokinet"},{"key":"1509_CR24","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.1994.12.3.532","volume":"12","author":"DS Sonnichsen","year":"1994","unstructured":"Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV (1994) Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12:532\u2013538","journal-title":"J Clin Oncol"},{"key":"1509_CR25","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-05-0298","volume":"11","author":"S Mielke","year":"2005","unstructured":"Mielke S, Sparreboom A, Steinberg SM et al (2005) Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11:4843\u20134850","journal-title":"Clin Cancer Res"},{"key":"1509_CR26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.1995.13.1.180","volume":"13","author":"L Gianni","year":"1995","unstructured":"Gianni L, Kearns CM, Giani A et al (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic\/pharmacodynamic relationships in humans. J Clin Oncol 13:180\u2013190","journal-title":"J Clin Oncol"},{"key":"1509_CR27","first-page":"4423","volume":"25","author":"S Mielke","year":"2005","unstructured":"Mielke S, Sparreboom A, Behringer D, Mross K (2005) Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. Anticancer Res 25:4423\u20134427","journal-title":"Anticancer Res"},{"key":"1509_CR28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.1997.15.1.317","volume":"15","author":"MT Huizing","year":"1997","unstructured":"Huizing MT, Giaccone G, van Warmerdam LJ et al (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European cancer centre. J Clin Oncol 15:317\u2013329","journal-title":"J Clin Oncol"},{"key":"1509_CR29","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2003.99.038","volume":"21","author":"A Sparreboom","year":"2003","unstructured":"Sparreboom A, Verweij J (2003) Paclitaxel pharmacokinetics, threshold models, and dosing strategies. J Clin Oncol 21:2803\u20132804 author reply 2805-6","journal-title":"J Clin Oncol"},{"key":"1509_CR30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s002800050932","volume":"43","author":"VR Nannan Panday","year":"1999","unstructured":"Nannan Panday VR, Hoetelmans RM, van Heeswijk RP et al (1999) Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi\u2019s sarcoma\u2013drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother Pharmacol 43:516\u2013519","journal-title":"Cancer Chemother Pharmacol"},{"key":"1509_CR31","unstructured":"Duchin K, Sun J, Tan M, Ilaw M, Cabriales S, Espina BM, East D, Tulpule A, Gill PS 1997 Pharmacokinetics of low-dose Paxene (paclitaxel) in patients with refractory or relapsed AIDS-related Kaposi\u2019s sarcoma. Proc Am Soc Clin. 15 Abstract 235"},{"key":"1509_CR32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO.20.1.153","volume":"20","author":"M Cianfrocca","year":"2002","unstructured":"Cianfrocca M, Cooley TP, Lee JY et al (2002) Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi\u2019s sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 20:153\u2013159","journal-title":"J Clin Oncol"},{"key":"1509_CR33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-4347(97)00502-1","volume":"705","author":"A Sparreboom","year":"1998","unstructured":"Sparreboom A, de Bruijn P, Nooter K, Loos WJ, Stoter G, Verweij J (1998) Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 705:159\u2013164","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"1509_CR34","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.1989.7.9.1201","volume":"7","author":"SE Krown","year":"1989","unstructured":"Krown SE, Metroka C, Wernz JC (1989) Kaposi\u2019s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS clinical trials group oncology committee. J Clin Oncol 7:1201\u20131207","journal-title":"J Clin Oncol"},{"key":"1509_CR35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.cco.0000239886.13537.ed","volume":"18","author":"L Pantanowitz","year":"2006","unstructured":"Pantanowitz L, Schlecht HP, Dezube BJ (2006) The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol 18:469\u2013478","journal-title":"Curr Opin Oncol"},{"key":"1509_CR36","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/01.aids.0000131385.60974.b9","volume":"18","author":"L Martin-Carbonero","year":"2004","unstructured":"Martin-Carbonero L, Barrios A, Saballs P et al (2004) Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi\u2019s sarcoma. Aids 18:1737\u20131740","journal-title":"Aids"},{"key":"1509_CR37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s002800051025","volume":"45","author":"L Fumagalli","year":"2000","unstructured":"Fumagalli L, Zucchetti M, Parisi I et al (2000) The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi\u2019s sarcoma. Cancer Chemother Pharmacol 45:495\u2013501","journal-title":"Cancer Chemother Pharmacol"},{"key":"1509_CR38","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00001813-200507000-00006","volume":"16","author":"BS Kappelhoff","year":"2005","unstructured":"Kappelhoff BS, Huitema AD, Mairuhu AT, Schellens JH, Beijnen JH (2005) No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. Anticancer Drugs 16:627\u2013630","journal-title":"Anticancer Drugs"},{"key":"1509_CR39","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2001.19.8.2171","volume":"19","author":"L Ratner","year":"2001","unstructured":"Ratner L, Lee J, Tang S et al (2001) Chemotherapy for human immunodeficiency virus-associated non-hodgkin\u2019s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19:2171\u20132178","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1509-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1509-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1509-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T14:45:04Z","timestamp":1559918704000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1509-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,5]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1509-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,5]]}}}